Aim To evaluate outcomes of ab interno trabeculectomy (AIT) with the trabectome following failed trabeculectomy.
Methods Prospective study of AITs and phaco-AITs after a failed trabeculectomy. The indication for AIT was intraocular pressure (IOP) above target on maximally tolerated therapy, and for phaco-AIT a visually significant cataract and need to lower IOP or glaucoma medications. Outcomes included IOP, medications, complications, secondary procedures and success, defined as IOP of less than 21 mm Hg and a greater than 20% reduction from baseline without further surgery. Exclusion criteria were trabeculectomy less than 3 months prior to AIT or follow-up under 1 year.
Results Seventy-three eyes of 73 patients with 1 year follow-up were identified. At 1 year, mean IOP in AIT significantly decreased by 28% from 23.7±5.5 mm Hg, and medications from 2.8±1.2 to 2±1.3 (n=58). In phaco-AIT, the mean IOP decreased 19% from 20±5.9 mm Hg and medications from 2.5±1.5 to 1.6±1.4 (n=15). Transient hypotony occurred in 7%, and further surgery was necessary in 18%. For AIT and phaco-AIT, the 1-year cumulative probability of success was 81% and 87%, respectively.
Conclusions Both AIT and phaco-AIT showed a reduction in IOP and medication use after 1 year, suggesting that AIT with or without cataract surgery is a safe and effective option following failed trabeculectomy.
- Treatment Surgery
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Trabeculectomy, introduced in the 1960s as an advancement from full thickness to guarded filtration, is still often called the standard of glaucoma surgery because it can achieve an average intraocular pressure (IOP) of 12.7±5.8 mm Hg at 1 year,1 and an average of 13.5±5.3 mm Hg in repeat trabeculectomy.2 It also has the highest complication rate of all current glaucoma treatment options with a rate of 39% early and 38% late potentially vision-threatening events adding up to a cumulative probability of 77% in a recent randomised controlled trial3 that is consistent with prior findings of a 78% cumulative complication rate.4 Performing this procedure a second time is less effective than the initial trabeculectomy.5
Ab interno trabeculectomy (AIT) with the trabectome (Neomedix, Inc., Tustin, California) is different from cautery because, similar to disruptive or ablative ophthalmic lasers, this plasma-mediated ablation uses ionisation and disintegration of trabecular meshwork (TM) with highly confined heat dissipation: histology showed no thermal damage to adjacent tissues or the outer wall with the exception of rare coagulation effects at the margins of the immediate ablation area.6 AIT can lower IOP in most types of open-angle glaucoma with an intact downstream drainage system and do so with a favourable safety profile.7 Since it is performed through a clear-corneal incision, subsequent filtration surgery is not affected.8 The efficacy of AIT following fistulating surgery has not been examined because it is usually performed in patients with ocular hypertension or early forms of glaucoma, while trabeculectomy is deemed appropriate for more advanced stages. An additional concern was that AIT after traditional trabeculectomy might be ineffective because of atrophy after the conventional outflow tract is bypassed.9 Subendothelial TM deposits and an amorphous material in the juxtacanalicular tissue narrowing the lumen were noted in human eyes following trabeculectomy, with a significant correlation between lower IOPs and smaller canals.10 Until now, it was not known whether Schlemm's canal and collector sizes may be too small for AIT to be successful even after IOP increased again in eyes that had failed filtration surgery.
The purpose of this study was to evaluate 1-year outcomes of the few AIT surgeries performed either alone or combined with phacoemulsification in patients with a failed trabeculectomy. We hypothesised, that by removing the diseased meshwork and subendothelial plaques, conventional outflow might be restored to a level that allows patients to avoid another filtration surgery and, that removal of more diseased tissue in advanced glaucomas might result in a more pronounced IOP response than at early stages.
Subjects were enrolled from the Trabectome Study Group database (previously described)7 ,11 with data relating to more than 5000 surgery outcomes, and divided into patients who had only AIT or AIT combined with phacoemulsification (phaco-AIT). AIT is a plasma surgery ablation technique that uses a bipolar 550 kHz electrode tip to remove the TM, the primary resistance to outflow. Approximately 120–180° of nasal TM was ablated.12 ,13 The main incisions were made by right-handed surgeons at 220° in right eyes and 20° in left eyes. The same incision was used in phaco-AIT for both parts of the procedure. Data for this study was collected with institutional review board approval, in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act.
This prospective interventional cohort included all patients with a diagnosis of glaucoma (with or without visually significant cataract), who had a failed trabeculectomy at least 3 months prior, and had at least 1 year of follow-up. Subjects were excluded if they had missing preoperative IOP data, end-stage visual field (VF) damage, or had AIT combined with any other procedure besides phacoemulsification.
The indication for AIT consisted of IOP above target with worsening glaucoma on maximally tolerated medical or laser therapy. The specific target IOP was set on a case-by-case basis by the individual treating physician as the maximum IOP estimated to prevent further nerve damage. The indication for phaco-AIT consisted of a visually significant cataract with at least 20/50 on brightness acuity test and the need to lower IOP or the number of glaucoma medications. VF status of all patients was categorised as early, moderate, or advanced by individual glaucoma specialists based on the most recent Humphrey VF exams (Zeiss, Jena, Germany). When VFs could not be categorised, for instance, due to non-glaucomatous VF changes, or unreliable test performance by software assessment, exams were categorised as ‘other’ not to confound stratification. All patients had a comprehensive slit lamp and ophthalmoscopy exam prior to surgery.
We compared IOP measured by Goldmann applanation tonometry and the number of glaucoma medications within each group using the paired t test. A finding of p<0.05 was considered statistically significant. All visual acuities were converted to logarithm of the minimum angle of resolution (logMar). Survival plots were created using Kaplan–Meier survival analysis. Success was defined as a final IOP of less than 21 mm Hg and a greater than 20% reduction from baseline without further surgery. Scattergrams were used to illustrate the proportions of study subjects who met various criteria for success.
After applying the exclusion criteria, a total of 73 eyes in 73 patients were identified who were treated with AIT after failed trabeculectomy that were followed for a minimum of 1 year (figure 1). Baseline patient demographics are presented in table 1.
Figure 2 shows the preoperative and postoperative IOP measurements and change in glaucoma medications over time in AIT and phaco-AIT, respectively. In the AIT group, the mean IOP was reduced from 23.7±5.5 to 16.2±3.9 mm Hg (28% mean reduction, p<0.01) and the number of medications was reduced from 2.8±1.2 to 2.0±1.3 (p<0.01) at 1 year. In the phaco-AIT group, the mean IOP was reduced from 20.0±5.9 to 15.6±5.1 mm Hg (19% mean reduction, p=0.11), while the mean number of medications was reduced from 2.5±1.5 to 1.6±1.4 (p=0.24) at 1 year.
Stratifying all cases by VF status (figure 3), subjects with mild or moderate VF status had a mean baseline IOP of 24.1±5.3 mm Hg which was reduced to 17.1±4 mm Hg at 1 year (24% reduction, p<0.01). The mean number of glaucoma medications was reduced from 2.2±1.2 to 1.8±1.2 at 1 year (p=1.0). Patients with advanced VF status had a mean baseline IOP of 22.9±5 mm Hg which was reduced to 15±4.3 mm Hg at 1 year (31% reduction, p<0.01). The mean number of glaucoma medications was reduced from 3±1.2 to 2±1.4 at 1 year (p=0.04).
Figure 4 shows the survival plots for AIT and phaco-AIT. For AIT and phaco-AIT, the 1-year cumulative probability of success was 81% and 87%, respectively. Table 2 presents success proportions by various success criteria, and figure 5 shows scattergrams that allow for visualisation of individual outcomes at 12 months that are captured by those criteria.
Table 3 presents secondary procedures and complications. A total of 13 cases (18%) went on to require further glaucoma surgery within 1 year. Five subjects (7%) had transient hypotony (IOP<5), but in all these cases, the hypotony spontaneously resolved and there was no loss of vision. There were no reported cases of aqueous misdirection, infection, wound leaks, choroidal effusion, or suprachoroidal haemorrhage.
Trabeculectomy has long been considered the standard for surgical treatment of glaucoma. Recently, epibulbar glaucoma drainage devices have been shown to be similarly effective.3
In this study, we evaluated for the first time the outcomes of AIT and phaco-AIT in subjects with glaucoma who had previously failed trabeculectomy. Such minimally invasive glaucoma procedures had been hypothesised to be ineffective after outflow tract bypassing surgery, and generally thought to be less effective than traditional glaucoma drainage procedures. We found that after 1 year, AIT performed alone showed a statistically significant decrease in IOP and in the number of glaucoma medications, while phaco-AIT resulted in a similar trend but did not reach statistical significance for medications (given difference of means and SD observed, the sample size would have to be at least 20). Furthermore, the effect was similar when stratified by VF status. Our results suggest that AIT may offer an attractive therapeutic option for patients who require further IOP lowering after failed glaucoma surgery, and especially in those who are unwilling or unable to tolerate repeat traditional glaucoma surgery.
In this study, the mean IOP decreased by 28% from a baseline of 23.7 mm Hg after AIT, and by 19% from a baseline of 20 mm Hg after phaco-AIT, which matches previous reports that also report a higher baseline IOP in the AIT group.14 ,15 In common with those studies, and reflecting different indications, IOP reduction was greater in AIT alone compared with the phaco-AIT group. Francis and colleagues reported a 1-year phaco-AIT case series of 304 subjects with an overall success rate of 64%, defining success as ≥20% drop in IOP, or a decrease in glaucoma medications without the need for additional medications or glaucoma procedures, including laser trabeculoplasty.15 Olali reported an 82% success (defined as IOP≤21 mm Hg) 1 year after a repeat trabeculectomy with mitomycin-C following a failed trabeculectomy.2 In our study, 89% of AIT and 92% of phaco-AIT patients had an IOP below 21 mm Hg at 12 months. Although surgical successes cannot be compared directly, it is possible that patients who are phenotypically more likely to fail trabeculectomy due to fibrosis will fail the same procedure again from the same cause, while fibrosis may not play a primary role in ab interno trabeculectomy.
When conventional outflow is decreased following trabeculectomy,9 the TM develops subendothelial deposits.10 The findings reported here suggest that the distal outflow tract does not irreversibly atrophy, and that natural outflow can be restored. When stratifying results by baseline VF status as a surrogate for glaucoma status, IOP was lower in the group with more advanced disease, suggesting that removal of a more diseased outflow resistance can result in a larger decrease in IOP.
Our study had several limitations, including a potential selection bias towards worse outcomes, as only the initial 20 cases are required to be submitted to the Trabectome Study Group Database to obtain full certification followed by subsequent voluntary reporting. Though this was a prospective cohort, it is based on a limited sample size with a relatively short-term follow-up.
In conclusion, AIT can be considered a viable therapeutic option for patients with a history of previously failed trabeculectomy who require further IOP lowering and are unwilling or unable to tolerate conventional glaucoma surgery.
Contributors IIB, KK, NAL and JSS contributed equally to data analysis and manuscript writing. NAL designed the study.
Competing interests NAL is a trabectome wetlab instructor.
Ethics approval Institutional review board.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.